Dobutamine (Dobutrex) 1ST LINE |
ฮฒโ > ฮฒโ agonist |
2โ20 mcg/kg/min IV |
โ CO, โ HR, mild โ SVR (ฮฒโ vasodilation). Net MAP may be unchanged or slightly โ. |
First-line inotrope in most cardiogenic shock (if MAP adequate). Septic shock with cardiac dysfunction. Augments diuresis in acute HF. |
Never use alone if MAP < 65 -can drop BP via ฮฒโ vasodilation. Always pair with NE if hypotensive. Tachycardia dose-limiting. Arrhythmogenic (โ Oโ demand). Tachyphylaxis after 72h (downregulation of ฮฒ-receptors). |
Milrinone (Primacor) 1ST LINE |
PDE3 inhibitor (โ cAMP) |
0.125โ0.75 mcg/kg/min IV (skip loading dose in ICU -causes hypotension) |
โ CO, โ SVR, โ PVR. "Inodilator" -inotropy + vasodilation. Better lusitropy (diastolic relaxation) than dobutamine. |
RV failure / pulmonary HTN (โ PVR is key advantage). Post-cardiac surgery. Bridge to LVAD/transplant. Works when ฮฒ-receptors are downregulated (chronic HF on BB) -bypasses ฮฒ-receptor. |
Hypotension (vasodilation) -more than dobutamine. Renally cleared -dose-adjust in AKI/CKD. Thrombocytopenia (rare). Longer half-life (2โ3h) -effects persist after stopping. Do NOT give loading dose in ICU (severe hypotension). |
Epinephrine (Adrenalin) 2ND LINE |
ฮฑโ + ฮฒโ + ฮฒโ agonist |
Low dose: 0.01โ0.1 mcg/kg/min (ฮฒโ/ฮฒโ dominant โ inotropy + vasodilation) High dose: 0.1โ0.5 mcg/kg/min (ฮฑโ dominant โ vasoconstriction + inotropy) |
โ CO, โ HR, dose-dependent SVR. Low dose = inotrope. High dose = inopressor. |
Refractory cardiogenic shock (need both inotropy + pressor). Cardiac arrest. Post-arrest low CO. Anaphylaxis. |
Falsely elevates lactate (ฮฒโ-mediated aerobic glycolysis) -cannot use lactate to guide resuscitation. Arrhythmogenic. โ myocardial Oโ demand. Hyperglycemia. Mesenteric ischemia at high doses. |
Dopamine (Intropin) AVOID |
Dose-dependent: Dโ (low) โ ฮฒโ (mid) โ ฮฑโ (high) |
"Renal dose" 1โ3 โ "cardiac" 3โ10 โ "pressor" 10โ20 mcg/kg/min |
Variable. Unpredictable hemodynamics. |
Avoid. Inferior to NE in shock SOAP II, 2010. Only remaining role: symptomatic bradycardia if no pacing. |
More arrhythmias and higher mortality vs NE. "Renal-dose dopamine" is a myth -no renal protection Bellomo, 2000. Unpredictable dose-response. Avoid in ICU. |
Levosimendan (Simdax) SPECIALIZED |
Calcium sensitizer + K-ATP channel opener |
0.05โ0.2 mcg/kg/min IV ร 24h |
โ CO, โ SVR, โ PVR. Inotropy without โ Oโ demand (unique). Active metabolite lasts 7โ9 days. |
Decompensated HF (Europe -not FDA-approved in US). Post-cardiac surgery. Bridge. Does not increase myocardial Oโ demand (unlike all other inotropes). |
Not available in the US. Hypotension. Effect lasts days after stopping (long-acting metabolite). Limited data vs milrinone. |
Isoproterenol (Isuprel) SPECIALIZED |
Pure ฮฒโ + ฮฒโ agonist (no ฮฑ) |
2โ20 mcg/min IV |
โ HR, โ CO, โ SVR. Potent chronotrope. |
Symptomatic bradycardia (bridge to pacing). Torsades de Pointes (โ HR shortens QT). Beta-blocker overdose. Post-heart transplant (denervated heart -atropine doesn't work). |
Severe hypotension (โ SVR via ฮฒโ). Massively increases myocardial Oโ demand. Arrhythmogenic. Never use in ischemia. |
Digoxin (Lanoxin) ADJUNCT |
Naโบ/Kโบ-ATPase inhibitor โ โ intracellular Caยฒโบ |
0.125โ0.25 mg PO/IV daily Load: 0.25โ0.5 mg IV |
Mild โ CO, โ HR (vagotonic). Weak inotrope compared to IV agents. |
Chronic HFrEF with persistent symptoms on GDMT. Afib rate control adjunct (especially HFrEF). DIG, 1997: reduced HF hospitalizations, no mortality benefit. |
Narrow therapeutic window (target 0.5โ0.9 ng/mL). Toxicity: any arrhythmia -classically "regularized Afib" (junctional rhythm), bigeminy, bidirectional VT. Hypokalemia potentiates toxicity. Renally cleared -dose-adjust. Reversal: digoxin-specific Fab (DigiFab). |